Sarcomatrix

Sarcomatrix, Inc. is a bio-pharmaceutical company pioneering novel therapeutics that leverage our understanding of muscle biology and tissue regeneration to develop therapies that have potential for broad clinical applicability across multiple disease areas of high unmet need. Our current focus is muscular dystrophy. Muscular dystrophy, a rare disease without a cure, reduces a patient's average life expectancy to 26 years. Our goal is to more than double their life expectancy. Our IP protected vast portfolio of small molecules a7β1 integrin activators and laminin proteins, used as single agents or in combination with cell and gene therapy, may ultimately cure muscular dystrophy.